πΒ·Jun 25Industry
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Publisher
O
Oramed Pharmaceuticals
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Oramed Pharmaceuticals
- Region
- ζζ°
- Scope
- Industry
- Published
- June 25, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on oramed.com
Leave the platform to read the original full article on the publisher site.
Source: Oramed Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
Eledon Pharmaceuticals/3h ago
Tegoprubart Sustains Increased eGFR Longterm Compared to Tacrolimus
Eledon Pharmaceuticals/3h ago
All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study
Allogene Therapeutics/7h ago
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics/7h ago